ArticleSurgical endoscopy2026
Clinical outcomes of plastic versus self-expanding metal stents in malignant hilar biliary obstruction.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant hilar biliary obstruction (MHBO) is a challenging condition with a poor prognosis, often requiring palliative biliary drainage. Endoscopic placement of plastic stents (PS) or self-expanding metal stents (SEMS) are the preferred approaches, but the optimal choice remains under debate. This study compares the clinical outcomes, patency, and survival associated with PS and SEMS in patients with unresectable MHBO.
methodsThis retrospective study analyzed patients with MHBO who underwent endoscopic drainage between January 2015 and December 2022 at a tertiary cancer center. Clinical success, stent patency, survival, and reintervention rates were compared between patients receiving PS or SEMS. Cox proportional hazards models and Kaplan-Meier survival analyses were used to evaluate outcomes.
resultsA total of 86 patients were included, with 39 (45.3%) receiving SEMS and 47 (54.7%) receiving PS. Clinical success was higher in the SEMS group (76.9% vs. 51.1%; p = 0.015), but this association was not confirmed in multivariate analysis. SEMS demonstrated significantly longer patency (median 213 vs. 78 days; p = 0.01) and a lower risk of recurrent biliary obstruction (HR 3.17, 95% CI 1.60-6.27; p = 0.001). However, overall survival did not differ significantly between groups (p = 0.059). Multivariate analysis identified better ECOG status (0-2) and bilirubin levels < 10 mg/dL as independent predictors of clinical success and longer survival.
conclusionSEMS provide superior patency compared to PS but did not significantly impact overall survival. Clinical success was influenced by ECOG performance status and baseline bilirubin levels rather than stent type alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.